Want to see IN:SENORES full AI Analyst Report?
SENORES Stock Chart & Stats
₹716.90
--
Market closed
₹716.90
--
Day’s Range― - ―
52-Week Range₹632.50 - ₹1,509.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)11.47K
Market Cap
₹59.94B
Enterprise Value₹32.25K
Total Cash (Recent Filing)₹3.60B
Total Debt (Recent Filing)₹2.41B
Price to Earnings (P/E)45.9
Beta0.97
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.35
Shares Outstanding46,053,590
10 Day Avg. Volume13,254
30 Day Avg. Volume11,469
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.63
Price to Sales (P/S)5.35
P/FCF Ratio-16.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)36.6
Revenue Forecast (FY)₹8.56B
Bulls Say, Bears Say
Bulls Say
Revenue Rebound & MarginsFY2026's ~151% revenue rebound combined with high gross and operating margins indicates the company achieved meaningful scale and improved unit economics. Sustained margins provide a durable earnings base to fund R&D, capacity and market expansion, strengthening long-term profitability if demand and cost discipline persist.
Improving LeverageThe modest deleveraging (debt-to-equity down to ~0.37) and rising equity balance signal improving capitalization. Lower leverage reduces refinancing and interest-coverage pressure, giving management more financial flexibility to invest strategically or withstand cyclical stress over the medium term without immediate balance-sheet strain.
Operating Cash Flow RecoveryThe move to positive operating cash flow suggests early restoration of cash generation aligned with reported earnings. If this OCF trend persists, the company can better fund working capital and capex internally, reduce external financing needs, and convert reported profitability into durable cash returns that bolster balance-sheet resilience.
Bears Say
Persistent Negative FCFSustained deeply negative free cash flow (~-2.03B) implies heavy capex or working-capital absorption that consumes cash despite reported profits. Over the medium term, persistent negative FCF forces reliance on debt or equity funding, increasing leverage, dilution risk, and constraining the company's ability to self-fund growth or weather downturns.
Weak Cash ConversionA material gap between reported profits and operating cash flow indicates weak earnings quality and possible receivable/inventory build or non-cash adjustments. This undermines confidence that strong margins are sustainable in cash terms and raises the risk that earnings volatility will translate into liquidity pressure or require recurring external funding.
Data Quality & VolatilityDocumented FY2025 data inconsistencies and sharp year-to-year profitability swings impair trend analysis and forecasting. Poor data reliability increases modelling risk, complicates credit assessment and investor due diligence, and elevates the chance of unexpected restatements or covenant problems, which is a structural governance and risk concern.
Senores Pharmaceuticals Ltd. News
SENORES FAQ
What was Senores Pharmaceuticals Ltd.’s price range in the past 12 months?
Senores Pharmaceuticals Ltd. lowest stock price was ₹632.50 and its highest was ₹1509.20 in the past 12 months.
What is Senores Pharmaceuticals Ltd.’s market cap?
Senores Pharmaceuticals Ltd.’s market cap is ₹59.94B.
When is Senores Pharmaceuticals Ltd.’s upcoming earnings report date?
Senores Pharmaceuticals Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 91 days.
How were Senores Pharmaceuticals Ltd.’s earnings last quarter?
Senores Pharmaceuticals Ltd. released its earnings results on Jul 27, 2026. The company reported ₹6.7 earnings per share for the quarter, beating the consensus estimate of ₹5.81 by ₹0.89.
Is Senores Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Senores Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Senores Pharmaceuticals Ltd. pay dividends?
Senores Pharmaceuticals Ltd. does not currently pay dividends.
What is Senores Pharmaceuticals Ltd.’s EPS estimate?
Senores Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senores Pharmaceuticals Ltd. have?
Senores Pharmaceuticals Ltd. has 46,053,590 shares outstanding.
What happened to Senores Pharmaceuticals Ltd.’s price movement after its last earnings report?
Senores Pharmaceuticals Ltd. reported an EPS of ₹6.7 in its last earnings report, beating expectations of ₹5.81. Following the earnings report the stock price went up 1.829%.
Which hedge fund is a major shareholder of Senores Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:SENORES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Senores Pharmaceuticals Ltd.
Established in 2017 and headquartered in Ahmedabad, India, Senores Pharmaceuticals Ltd. is actively involved in the development, manufacturing, and global commercialization of pharmaceutical and related products. Its extensive portfolio reaches markets across India, the United States, the United Kingdom, Canada, and other international territories. The company specializes in a diverse array of therapeutic solutions, encompassing analgesics/antipyretics, anesthetics, antibacterials, antivirals, antifungals, antioxidants, antineoplastics, blood-related therapies, cardiovascular and neurological medications, antacids, and vitamin and mineral supplements. Additionally, Senores offers a selection of generic drugs targeting pain, inflammation, fever, diabetes, malaria, and urinary tract conditions, as well as neutral supplements. Complementing its product offerings, the firm also provides management and consultancy services.
Technical Analysis
Balaxi Pharmaceuticals Limited
―
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Lasa Supergenerics Ltd.
―
Sakar Healthcare Ltd
―